LONDON – On Tuesday, Pfizer (NYSE: PFE) and its German partner BioNTech (NASDAQ: BNTX) won their attempt to invalidate two […]
Pfizer and BioNTech Win Bid to Invalidate CureVac’s UK COVID Vaccine Patents Read More »
U.S. sales of RSV vaccines from GSK (NYSE: GSK) and Pfizer (NYSE: PFE) are down significantly after regulators narrowed the
Pfizer and GSK RSV Vaccine Sales Fall in US as Millions Fewer People Line Up Read More »
LONDON – On Monday, Pfizer (NYSE: PFE) won a bid in a London court to invalidate two of GSK’s (NYSE:
Pfizer Secures Legal Victory Against GSK in RSV Vaccine Patent Dispute Read More »
Pfizer (NYSE: PFE) sold a stake in British consumer healthcare group Haleon (NYSE: HLN) worth about $3.26 billion on Monday,
Pfizer (NYSE: PFE) Cuts Haleon Stake to 15%, Selling $3.3 Billion in Shares Read More »
On Thursday, the European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer’s (NYSE: PFE) sickle cell disease drug
EU Regulator Recommends Suspension of Pfizer’s Sickle Cell Disease Treatment Read More »
Pfizer’s (NYSE: PFE) decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death
Analysts Say Pfizer’s Oxbryta Exit Could Speed Up Trials for Rival Sickle Cell Drugs Read More »
LONDON – Pfizer (NYSE: PFE) and Moderna’s (NASDAQ: MRNA) legal battle over their rival COVID-19 vaccines will continue after London’s
Pfizer vs. Moderna: COVID Vaccine Patents Battle to Go to Appeal in UK Read More »
On Thursday, the U.S. Food and Drug Administration approved updated COVID-19 vaccines made by Pfizer (NYSE: PFE) and Moderna (NASDAQ:
FDA Greenlights Updated COVID Vaccines to Combat New Variants Ahead of Fall Campaign Read More »
On Monday, Pfizer (NYSE: PFE) said its respiratory syncytial virus (RSV) vaccine Abrysvo generated a strong immune response in a
Pfizer’s (NYSE: PFE) RSV Vaccine Proves Effective for Immuno-Compromised Adults in Study Read More »
Copyright © 2024 abbonews.com
